drugset / Trial / NCT05740202

A Trial of SHR-7367 in Subjects With Advanced Solid Tumors

NCT05740202

Phase 1 Completed 22 enrolled Shanghai Hengrui Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a dose-escalation and dose-expansion Phase 1 trial to evaluate the safety and tolerability of SHR-7367 in subjects with advanced solid tumors.

Timeline

Start
2023-03-06
Primary completion
2025-08-04
Completion
2025-08-04

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-7367 Unknown

Indications